Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled time : 12:00 save search
Avenue Therapeutics Announces Reverse Stock Split
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
FBIO | $1.79 -1.11% -1.4% 120K
|
Health Technology
|
| O: -0.56%
H: 0.56%
C: 0.0%
ATXI | $0.0943 -29.63% -41.2% 12M
|
Health Technology
|
| O: -23.08%
H: 0.0%
C: -10.0%
therapeutics
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
KTTA | $6.9501 -1.97% -1.19% 910
|
|
| O: -2.68%
H: 0.72%
C: 0.72%
pas-004 first trial therapeutics
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
UTHR | $237.0 1.08% 1.09% 670K
|
Health Technology
|
| O: -0.56%
H: 3.16%
C: 1.45%
first report corporation therapeutics financial results market
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -3.1% -5.94% 23K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
asco
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.16 -0.07% -0.13% 530K
|
Health Technology
|
| O: 1.03%
H: 0.72%
C: -0.13%
positive treatment global for
Biopharma Layoff Tracker 2024: Tessera, BMS, Pfizer and More Cut Staff
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: -1.05%
RLYB | News | $1.58 -9.2% -9.43% 250K
|
|
| O: -3.05%
H: 0.0%
C: -9.71%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
VXRT | News | $0.7097 -4.79% -5.72% 1.4M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: -6.58%
TXMD | News | $1.92 2.13% -0.27% 15K
|
Health Technology
|
| O: 0.53%
H: 2.12%
C: 1.59%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
PTCT | News S | $25.21 -0.79% -0.87% 560K
|
Health Technology
|
| O: -0.71%
H: 0.81%
C: -2.25%
NKTR | News | $1.38 -2.82% -2.16% 960K
|
Health Technology
|
| O: -1.08%
H: 3.65%
C: 0.73%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 0.0%
H: 0.28%
C: 0.06%
GLPG | News | $28.77 -2.31% -2.33% 130K
|
Health Technology
|
| O: 0.48%
H: 0.17%
C: -1.88%
AMRN | News | $0.8786 -0.53% 0.12% 640K
|
Health Technology
|
| O: 0.57%
H: 1.14%
C: 0.0%
GOOGL | News 4 | $159.13 0.55% 0.58% 18M
|
Technology Services
|
| O: 0.29%
H: 1.31%
C: 1.04%
GOOG | News 4 | $161.1 0.74% 0.7% 16M
|
Technology Services
|
| O: 0.32%
H: 1.45%
C: 1.26%
OCX | News | $2.46 0.2% -6.74% 40K
|
Health Technology
|
| O: 2.03%
H: 0.0%
C: -1.99%
biopharma
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.39 -0.78% -0.55% 82K
|
Professional, Scientific, and T...
|
| O: 2.17%
H: 5.06%
C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
LSTA | $2.83 6.79% 5.02% 9.6K
|
Manufacturing
|
| O: -4.12%
H: 9.77%
C: 3.52%
first pancreatic trial therapeutics china
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CGTX | News | $1.99 -0.5% 0.0% 110K
|
|
| O: -2.17%
H: 7.78%
C: 3.33%
disease alzheimer’s treat for therapeutics platform
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
LXEO | News | $12.5 2.97% 2.45% 99K
|
|
| O: 3.42%
H: 5.56%
C: 2.01%
lx2006 license treatment for therapeutics agreement development
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M
|
Health Technology
|
| O: -6.86%
H: 6.89%
C: 4.6%
positive trial results
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.5 13.64% 13.16% 120K
|
Health Technology
|
| O: -6.06%
H: 4.84%
C: 2.42%
first osteoarthritis trial
Preliminary Results for the Year Ended 31 December 2023
Published: 2024-04-19 (Crawled : 12:00) - globenewswire.com
ATRX | $0.0075 11.94% 1724.82% 2K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: 0.0%
year for results
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
TGTX | $13.98 -1.9% -1.86% 2.4M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
briumvi neurology sclerosis for meeting therapeutics
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
MNPR | $0.657 1.08% -3.17% 39K
|
Health Technology
|
| O: 6.06%
H: 2.86%
C: -2.86%
nuclear presentation for meeting imaging molecular
Windtree Therapeutics Announces Reverse Stock Split
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
WINT | $5.155 -9.3% -11.77% 50K
|
Health Technology
|
| O: -30.25%
H: 0.0%
C: 0.0%
therapeutics
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1K
|
Health Technology
|
| O: -0.87%
H: 3.58%
C: -2.86%
nephropathy congress world nefecon trial therapeutics
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
ALDX | $3.94 0.77% 0.51% 570K
|
Health Technology
|
| O: 1.53%
H: 2.52%
C: 0.25%
day research therapeutics development
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
WINT | $5.155 -9.3% -11.77% 50K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
business key therapeutics financial results
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $37.02 -1.99% -2.15% 390K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.